Cardiovascular disease is responsible for 17 million deaths around the globe, making it the No. 1 cause of death worldwide, according to the American Heart Association and the World Health Organization. The disease is often onset by poor lifestyle choices, resulting in healthcare services, medications, and lost productivity that costs the United States more than $108 billion each year.
If individuals aren’t taking responsibility for their own health, the burden falls to forward-thinking companies willing to put in the time, effort, and research to address the disease and develop advanced therapies for treatment.
Cardium Therapeutics is a health sciences company focused on combining the mysterious complexity of biology with the power of regenerative medicine to develop new ways to treat cardiovascular disease and its morbid weight on the human race. The company’s strategy oversteps conventional approaches such as drug therapy, which only provides temporary relief, and invasive treatment options such as bypass surgery, angioplasty, and stents.
CXM’s medical portfolio includes Generx, a non-surgical angiogenic treatment option that actually enhances cardiac blood flow. Generx aligns with the heart’s natural healing process, using DNA to encourage microvascular blood vessel growth (angiogenesis) within the heart.
CXM believes that its angiogenic therapeutic approach is remarkably different from other potential angiogenic therapies, and that its approach holds several advantages over competitors. One such advantage is its intracoronary deliver technique, which utilizes a standard diagnostic catheter, creating the potential for a wider distribution of therapeutic material in the heart, as compared to direct needle injections into portions of the heart muscle.
The lead candidate has progressed through four randomized, placebo-controlled clinical studies at more than 100 medical centers in the United States and Western Europe that have enrolled more than 650 patients. CXM reports that within eight weeks of administering its Generx therapy, patients have experienced improved cardiac perfusion and angiogenesis.
For more information, visit www.CardiumThx.com
Please see disclaimer on the MissionIR website
http://www.missionir.com/disclaimer.html
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment